Brofaromine ? a review of its pharmacological properties and therapeutic use
- 1 January 1996
- journal article
- review article
- Published by Springer Nature in Journal Of Neural Transmission-Parkinsons Disease and Dementia Section
- Vol. 103 (1-2) , 217-245
- https://doi.org/10.1007/bf01292628
Abstract
The antidepressant activity of monoamine oxidase inhibitors has been well established for 30 years. Nevertheless, this group of compounds was handled with great care, mainly because of the interaction potential with tyramine-containing foodstuff. With the discovery of reversible and selective inhibitors of monoamine oxidase type A a renaissance of these compounds has begun. In this paper one of these new substances — brofaromine — will be described in detail. Biochemical and pharmacological aspects will be reviewed, showing that brofaromine is a selective and reversible inhibitor of monoamine oxidase type A with additional serotonin reuptake inhibiting properties. Both mechanisms of action may synergize in the antidepressant effect of the compound. The main results of clinical trials in depression and other indication areas will also be covered. Special attention will be put on the side effect profile.Keywords
This publication has 91 references indexed in Scilit:
- A Canadian multicentre placebo-controlled study of a fixed dose of brofaromine, a reversible selective MAO-A inhibitor, in the treatment of major depressionJournal of Affective Disorders, 1994
- Monoamine oxidase inhibition by the MAO-A inhibitors brofaromine and clorgyline in healthy volunteersJournal Of Neural Transmission-Parkinsons Disease and Dementia Section, 1994
- Serotonin SyndromeCNS Drugs, 1994
- Brofaromine in treatment-resistant depressed patients — a comparative trial versus tranylcypromineJournal of Affective Disorders, 1994
- Influence of food on the disposition of the monoamine oxidase‐A inhibitor brofaromine in healthy volunteersBiopharmaceutics & Drug Disposition, 1993
- Brofaromine in Panic Disorder: A Pilot Study with a New Reversible Inhibitor of Monoamine Oxidase-APharmacopsychiatry, 1992
- Psychopharmacological treatment of social phobia: clinical and biochemical effects of brofaromine, a selective MAO-A inhibitorEuropean Neuropsychopharmacology, 1992
- Effect of the selective MAO-A inhibitors brofaromine, clorgyline and moclobemide on human platelet MAO-B activityJournal Of Neural Transmission-Parkinsons Disease and Dementia Section, 1992
- Treatment strategy in depressionActa Psychiatrica Scandinavica, 1988
- Effects of Imipramine and Brofaromine, a Selective and Reversible MAO-A Inhibitor, on Novelty-oriented Behaviour in RatsPharmacopsychiatry, 1986